Rivaroxaban Diol
| CAS No. | 1160170-00-2 | Cat. No. | BCP07255 |
| Name | Rivaroxaban Diol | ||
| Synonyms | BAY59-7939; BAY 59-7939; BAY-59-7939;Mixture of Diastereomers; | ||
| Formula | C19H20ClN3O6S | M. Wt | 453.9 |
| Description | Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. If approved by the United States FDA, it will be marketed by Ortho-McNeil Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects lasts 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible. | ||
| Pathways | Protease/Metabolic Enzyme | ||
| Targets | Factor Xa | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.